Archives: 2019-08-26

Study Reveals Key Differences Between Three Frontline Breast Cancer Drugs

Source Harvard Medical School The findings of a new Harvard Medical School study suggest important differences between three frontline drugs used to treat advanced breast cancer. The researcher’s findings were published in Cell Chemical Biology. The three CDK4/6 inhibitors, abemaciclib, palbociclib, and ribociclib have exhibited exceptional efficacy in hindering breast tumor growth, improving survival rates and prompting FDA approval.

Read More


Deep learning enables scientists to identify cancer cells in blood in milliseconds

Technique could allow cells to be extracted in real time, help prevent cancer from spreading Researchers at UCLA and NantWorks have developed an artificial intelligence-powered device that detects cancer cells in a few milliseconds — hundreds of times faster than previous methods. With that speed, the invention could make it possible to extract cancer cells from blood immediately after

Read More


Organ-on-e-chip Biosensor Shrink Wraps Heart Cells

Researchers at Carnegie Mellon University (CMU) and Nanyang Technological University (NTU) in Singapore have developed an organ-on-an-electronic-chip biosensor technology that can measure the electrophysiology of heart cell structures in three dimensions. The biosensor array essentially self-rolls around elongated spheroids of stem cell-derived cardiac cells—similar to how a “slap bracelet” wraps around a wrist—giving researchers the

Read More


Do no harm: a roadmap for responsible machine learning for health care

Interest in machine-learning applications within medicine has been growing, but few studies have progressed to deployment in patient care. We present a framework, context and ultimately guidelines for accelerating the translation of machine-learning-based interventions in health care. To be successful, translation will require a team of engaged stakeholders and a systematic process from beginning (problem

Read More


FDA Approves JAK Inhibitor for Moderate to Severe Rheumatoid Arthritis

The FDA approved upadacitinib (Rinvoq, AbbVie), a 15-mg, once-daily oral Janus kinase inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate. The approval is supported by data from the SELECT program, one of the largest registrational phase 3 clinical programs

Read More


$9 million grant funds trial of CAR T-cell therapy for metastatic breast cancer

California Institute for Regenerative Medicine awarded a $9.28 million grant will support a clinical trial at City of Hope to evaluate chimeric antigen receptor T-cell therapy for patients with HER2-positive breast cancer that spread to the brain. About 20% of breast cancers are HER2-positive, and nearly half of women with this type of breast cancer develop brain

Read More